Narcotic antagonists

Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC 50 values of 0.8 nM, 110 nM, and 6500 nM, respectively.Navacaprant endows with favorable in vitro

Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC 50 values of 0.8 nM, 110 nM, and 6500 nM, respectively.Navacaprant endows with favorable in vitro

Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC 50 values of 0.8 nM, 110 nM, and 6500 nM, respectively.Navacaprant endows with favorable in vitro

InformationNMDA（N-Methyl-D-aspartic acid）is a specific agonist forNMDAreceptor mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor. Phase 4.In vitroNMDA is an excitatory amino acid neurotransmitter, which

NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925

NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925

NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925

Pentiapine (CGS 10746) is a dopamine release inhibitor without binding to synaptic dopamine receptor sitesIn VivoPentiapine is a novel dopamine release inhibitor.The results show that Pentiapine dose-dependently reduces motor activity of mice.

Pentiapine (CGS 10746) is a dopamine release inhibitor without binding to synaptic dopamine receptor sitesIn VivoPentiapine is a novel dopamine release inhibitor.The results show that Pentiapine dose-dependently reduces motor activity of mice.

Pentiapine (CGS 10746) is a dopamine release inhibitor without binding to synaptic dopamine receptor sitesIn VivoPentiapine is a novel dopamine release inhibitor.The results show that Pentiapine dose-dependently reduces motor activity of mice.

Biochem/physiol Actions NR2B-selective, noncompetitive NMDA glutamate receptor antagonist Features and Benefits This compound is featured on the Glutamate Receptors (Ion Channel Family) page of the Handbook of Receptor Classification and

Potent and selective TXA 2 antagonist.